5.25
-0.01 (-0.19%)
| Previous Close | 5.26 |
| Open | 5.22 |
| Volume | 478,472 |
| Avg. Volume (3M) | 561,121 |
| Market Cap | 438,597,088 |
| Price / Sales | 3.49 |
| Price / Book | 6.16 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2024 - 8 Nov 2024 |
| Profit Margin | -22.92% |
| Operating Margin (TTM) | -13.56% |
| Diluted EPS (TTM) | -0.670 |
| Quarterly Revenue Growth (YOY) | 18.10% |
| Total Debt/Equity (MRQ) | 80.05% |
| Current Ratio (MRQ) | 3.50 |
| Operating Cash Flow (TTM) | -40.24 M |
| Levered Free Cash Flow (TTM) | -29.19 M |
| Return on Assets (TTM) | -8.39% |
| Return on Equity (TTM) | -33.71% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Paragon 28, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 1.88 |
|
Paragon 28 Inc is a medical devices company that develops, distributes, and sells medical devices in the foot and ankle segment of the orthopedic implant marketplace. Its products include plates and plating systems, screws, staples, and nails aimed to address all major foot and ankle procedures including ankle, Charcot, fracture fixation, hallux valgus, hammertoe, and flat foot. The company's suite of surgical solutions comprises nearly 80 product systems to help fit the specific needs of each patient and procedure. Geographically the company generates the majority of its revenue from the United States. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Core |
| % Held by Insiders | 40.56% |
| % Held by Institutions | 60.95% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Mvm Partners, Llc | 30 Jun 2024 | 10,886,145 |
| First Light Asset Management, Llc | 30 Jun 2024 | 8,174,832 |
| Braidwell Lp | 30 Jun 2024 | 4,150,109 |
| Bleichroeder Lp | 30 Jun 2024 | 1,763,339 |
| Degroof Petercam Asset Management | 31 Mar 2024 | 974,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 15.00 (Canaccord Genuity, 185.71%) | Buy |
| Median | 14.00 (166.67%) | |
| Low | 13.00 (Needham, 147.62%) | Buy |
| Average | 14.00 (166.67%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 10.52 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 13 Jan 2025 | 13.00 (147.62%) | Buy | 10.74 |
| 13 Nov 2024 | 13.00 (147.62%) | Buy | 10.30 | |
| Canaccord Genuity | 13 Nov 2024 | 15.00 (185.71%) | Buy | 10.30 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |